Ventyx Biosciences is stopping work on its lead drug candidate in plaque psoriasis and psoriatic arthritis. Despite achieving the goals of its Phase 2 test in psoriasis, the results are short of those achieved by big pharmaceutical companies with molecules that address the same target.
My phone chimed with a notification, signaling the availability of a new CT test result in my online health portal. “Multiple bilateral pulmonary nodules measuring up to 8mm. May represent metastatic disease.” This was several weeks after my very first mammogram–which I underwent shortly after my 40th birthday–detected an anomaly on my left breast. I soon learned I had what are called “dense” breasts, which means I have compact breast tissue and typical imaging isn’t the best screening for me. My doctor ordered an MRI, which revealed a five-centimeter tumor on the right side, accompanied by lymph-node involvement. The results of the CT scan meant there was a possibility that I didn’t just have breast cancer, I could have breast cancer that had already spread to another part of my body. This type of cancer is called metastatic, and there’s no cure. I spent the next seven weeks in a state of utter panic, while also trying to maintain a sense of normalcy for my daughter
Kristina Jiali Fusella, Author at MedCity News medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
Baylor Medicine teamed up with Luna to launch a program expanding access to in-home physical therapy for patients in the Houston area. Luna, a provider of in-home physical therapy, has similar partnerships with more than two dozen health systems. These partnerships help health systems expand access to care and increase their geographic coverage across their markets, said Palak Shah, Luna’s co-founder.
The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA’s official publication of approved products. Such listings delay generic competition, which reduces consumer choice and keeps prices high, the regulator said.